Rivoglitazone Hydrochloride PPARγ Agonist Insulin Sensitizer Treatment of Diabetes

被引：1
|
作者：
Davies, S. [1 ]
Castaner, R. [1 ]
Bolos, J. [1 ]
机构：
[1] Prous Sci, Barcelona 08025, Spain
来源：
DRUGS OF THE FUTURE | 2008年 / 33卷 / 11期
关键词：
CI-1037; CS-011; DE-101; R-106056;
D O I：
10.1358/dof.2008.033.011.1278754
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The complex metabolic disorder type 2 diabetes is a leading cause of morbidity and mortality worldwide and thus a health and economic burden. Daiichi Sankyo, has developed a new thiazolidinedione candidate for the treatment of type 2 diabetes, rivoglitazone hydrochloride (CS-011). In vitro, rivoglitazone demonstrates increased agonist activity at the peroxisome proliferator-activated receptor PPAR gamma compared to rosiglitazone, with in vivo and clinical studies confirming its enhanced antidiabetic activity compared with other thiazolidinediones. Rivoglitazone is currently undergoing phase II/III clinical development for the treatment of type 2 diabetes.
引用
收藏
页码：926 / 931
页数：6
相关论文
共 50 条
  • [1] The effects of rivoglitazone (PPARγ agonist) on adiponectin in healthy subjects
    Triscari, Joseph
    Dmuchowski, Carl
    DIABETES, 2006, 55 : A136 - A136
  • [2] CLX-0940: A non thiazolidinedione PPAR agonist and insulin sensitizer
    Neogi, P
    Dey, D
    Medicharla, S
    Frederick, L
    Nag, B
    DIABETES, 2000, 49 : A362 - A362
  • [3] Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action
    Zierath, JR
    Ryder, JW
    Doebber, T
    Woods, J
    Wu, M
    Ventre, J
    Li, ZH
    McCrary, C
    Berger, J
    Zhang, B
    Moller, DE
    ENDOCRINOLOGY, 1998, 139 (12) : 5034 - 5041
  • [4] Potent antidiabetic effects of rivoglitazone, a novel PPARγ agonist, in obese diabetic rodent models
    Ohsumi, J.
    Kanda, S.
    Tanaka, J.
    Takahashi, K.
    Nakashima, R.
    Koieyama, N.
    Hagisawa, Y.
    Araki, K.
    DIABETOLOGIA, 2007, 50 : S353 - S353
  • [5] Tesaglitazar.: Treatment of type 2 diabetes, treatment of metabolic syndrome, PPARα/PPARγ agonist
    McIntyre, JA
    Castañer, J
    Bayés, M
    DRUGS OF THE FUTURE, 2003, 28 (10) : 959 - 965
  • [6] Chronic PPARα and γ agonist treatment in the prevention of diabetes in ZDF rats
    Bergeron, R
    Yao, J
    Woods, JW
    Zycband, EI
    Zhang, BB
    Moller, DE
    Doebber, TW
    DIABETES, 2002, 51 : A34 - A35
  • [7] Muraglitazar -: Treatment of type 2 diabetes -: Dual PPARα/γ agonist
    McIntyre, JA
    Castañer, J
    DRUGS OF THE FUTURE, 2004, 29 (11) : 1084 - 1087
  • [8] The influence of PPAR-α agonist treatment on insulin sensitivity in patients with type 2 diabetes:: the role of resistin and adiponectin
    Dolezalova, R.
    Anderlova, K.
    Housova, J.
    Bosanska, L.
    Skrha, J.
    Haluzik, M.
    DIABETOLOGIA, 2006, 49 : 340 - 341
  • [9] A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes
    Kong, A. P. S.
    Yamasaki, A.
    Ozaki, R.
    Saito, H.
    Asami, T.
    Ohwada, S.
    Ko, G. T. C.
    Wong, C. K.
    Leung, G. T. C.
    Lee, K. F.
    Yeung, C. Y.
    Chan, J. C. N.
    DIABETES OBESITY & METABOLISM, 2011, 13 (09): : 806 - 813
  • [10] Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus
    Lecka-Czernik, Beata
    IDRUGS, 2010, 13 (11) : 793 - 801
12345